Top Health News Briefs: Drug Trials, IPOs, Vaccination Campaigns, and Legal Battles

This material provides a summary of current health news, covering topics such as Nvidia-backed Recursion's mixed drug trial results, BioAge Labs' US IPO, WHO's findings on mobile phones and brain cancer, Aspen's GLP-1 drug plans, polio vaccinations in Gaza, the US Supreme Court ruling on Oklahoma's family planning grant, Aspen's mpox vaccine talks, Rite Aid's transition after bankruptcy, US drug pricing, and Illumina's legal victory regarding its Grail acquisition.

Nvidia-backed Recursion Pharmaceuticals said its experimental drug for a rare brain disorder showed mixed efficacy in a mid-stage trial, causing its shares to drop by 14%. BioAge Labs, a startup focusing on obesity therapies, filed for a US IPO to benefit from the current investor enthusiasm in the biotech sector.

The WHO reported no link between mobile phone use and brain cancer in a comprehensive global study. Aspen Pharmacare aims to boost profits through GLP-1 drug contracts after missing its profit growth target, and reported a 13.23% drop in shares.

The WHO's polio vaccination campaign in Gaza has surpassed its targets, inoculating about a quarter of children under 10. The US Supreme Court has allowed the Biden administration to cut federal funding for family planning projects in Oklahoma amid an abortion dispute. Rite Aid will operate as a private company after completing its financial restructuring.

In other news, US drug prices remain higher despite negotiated reductions. Illumina won a court fight against the EU, limiting Brussels' merger powers regarding its $7.1 billion acquisition of Grail. Aspen Pharmacare is also negotiating to manufacture mpox vaccines to address a health emergency in Africa.

(With inputs from agencies.)